Outcome after gastrectomy in gastric cancer patients with type 2 diabetes

Table 5 Subgroup analysis [body mass index reduction ratio < 10%, n = 206, n (%) or mean ± SD]

		Diabetes course				P value
		Worse	Same	Improvement	Remission
Gender	Female	3 (8.1)	17 (45.9)	14 (37.8)	3 (8.1)	0.190
	Male	21 (13.0)	85 (52.8)	43 (26.7)	12 (7.5)
Age at OP (yr)		61.9 ± 8.1	63.9 ± 8.0	63.8 ± 7.5	61.1 ± 9.3	0.976
OP type	B-Ia	14 (13.5)	56 (53.8)	27 (26.0)	7 (6.7)	0.076
	B-IIa	7 (11.3)	33 (53.2)	18 (29.0)	4 (6.5)	0.181
	R-Y	3 (9.4)	13 (40.6)	12 (37.5)	4 (12.5)
Extent of gastrectomy	Subtotal (B-I, B-II)	21 (12.7)	89 (53.6)	45 (27.1)	11 (6.6)	0.084
	Total (R-Y)	3 (9.4)	13 (40.6)	12 (37.5)	4 (12.5)
Duodenal bypass	Bypass – (B-I)	14 (13.5)	56 (53.8)	27 (26.0)	7 (6.7)	0.250
	Bypass + (B-II, R-Y)	10 (10.6)	46 (48.9)	30 (31.9)	8 (8.5)
Pre-OP BMI (kg/m2)		22.7 ± 2.3	24.3 ± 2.7	23.8 ± 3.0	22.2 ± 2.8	0.615
Current BMI (kg/m2)		22.3 ± 2.2	23.4 ± 2.6	23.0 ± 3.1	21.3 ± 2.6	0.310
BMI reduction ratio1 (%)		1.5 ± 6.6	3.7 ± 4.5	3.6 ± 5.9	4.2 ± 4.6	0.183
Pre-OP	Oral diabetic agent	24 (13.5)	93 (52.2)	47 (26.4)	14 (7.9)	0.080
diabetic
regimen	Insulin	0 (0.0)	9 (45.0)	10 (50.0)	1 (5.0)
F/U duration (mo)		37.7 ± 17.6	38.8 ± 21.7	30.7 ± 20.7	28.7 ± 14.1	0.022

^aP = 0.674, B-I vs B-II; OP: Operation; BMI: Body mass index; F/U: Follow up; B-I : Billroth I; B-II: Billroth II; R-Y: Roux-en-Y;

¹BMI reduction ratio (%) = -[(Current BMI - Pre-OP BMI)/Pre-OP BMI] × 100.